Avania’s Post

As the year comes to a close—just weeks ahead of the JPMorgan Healthcare Conference—I’m excited to announce our latest collaboration, further expanding our global network of academic partnerships, research sponsorships, and research organizations. Our acceleration program with Eretz.bio, in collaboration with the Hospital Albert Einstein, represents a significant step forward. This partnership allows us to leverage the clinical and research expertise of a center of excellence in neurology and neurodegenerative diseases, reinforcing our commitment to a patient-centric approach in drug discovery and development. This collaboration is especially meaningful to me, as it brings Brazil—my home country and the nation with the second-highest age-standardized prevalence of dementia globally—into our growing network.

We are pleased to announce that Momentum Therapeutics has been selected to participate in Eretz.bio's biotech acceleration program in collaboration with Hospital Albert Einstein, ranked among the top 35 global hospitals and renowned for excellence in neurology. This partnership represents a significant milestone for Momentum and will drive the advancement of our innovative programs while reinforcing our commitment to a patient-centric approach in drug discovery and development.

Intraoperative Imaging Market Set for Major Growth! 🌐 From neurosurgery to oncology, real-time imaging is transforming surgical precision. With the market projected to grow from $2.9B in 2023 to $4.85B by 2032, now’s the time to stay ahead of the curve. 📊 Discover the key trends, drivers, and challenges shaping the future of this vital market. 📥 Download the full report for in-depth insights and projections 🔗 https://lnkd.in/dSRrKe64 #SNSInsider #GrowWithSNS #MarketReports #HealthcareInnovation #DownloadNow

Join us for Bio2DeviceGroup's event tomorrow Feb 12 at 6 pm PST for a talk on "Empowering Personalized Care: Pioneering the Right Treatment for the Right Person at the Right Time" by Maital (Shemesh) Rasmussen. See link to join in comments. With real-world examples from diverse fields like oncology and neurology, this presentation will explore the evolution of #precisionmedicine where tailored treatments are likely to revolutionize healthcare practices. - With Harry Wachob Patrick Lee Stan Levy RONALD SCHOENGOLD, RAC, FRAPS

Exhibition of the week: The 8th Complement-Based Drug Development Summit! (https://hubs.ly/Q02-X4F_0) We’re excited to showcase Svar Life Science's innovative solutions at this premier event for complement-targeted therapies. As the complement community gathers to share new discoveries and tackle challenges, we’re here to demonstrate how Svar's complement solutions can support your research and development. Our assays are designed to help you explore the complement pathways with precision science, providing critical insights across applications in ophthalmology, neurology, oncology, and more. Meet our team of experts to discover how Svar can accelerate your work in this evolving field. #complement #ComplementSystem #complementpathway #drugdevelopment #clinicalassays #ELISA #functionalassay

The rise of personalized medicine is reshaping the pharmaceutical landscape, with 𝟲𝟴% of surveyed physicians already integrating it into their practice. Our research indicates that the market will grow at a CAGR of 𝟭𝟭.𝟰%, driven primarily by oncology, cardiology, and neurology. Despite strong adoption, concerns about costs persist, highlighting the need for affordable solutions. North America and Europe lead the market, while Asia-Pacific shows significant investment in research. As AI and genetic testing gain traction, personalized medicine offers promising growth. Explore our latest insights at GRG Health. https://lnkd.in/gV_DwF5y #PersonalizedMedicine #PharmaTrends #HealthcareInnovation #Genomics #Oncology #Cardiology #AIinHealthcare #MarketResearch #GeneticTesting #GRGHealth Manan Sethi

The first multi clip localization case in the world 🌎 using the new SCOUT MD system by Merit Medical Oncology. Starting with two site localization under mammography 🩻, the clips functioned perfectly for a two site lumpectomy targeting calcifications using a single periareolar incision 😷. Having the ability to toggle through each clip’s unique feedback individually or simultaneously allows for precise adjustment during dissection in cases requiring multi-site localization and/or bracketing. In this particular case, this technology allowed for resection of the areas as one specimen and reduced overall volume of tissue. GAME CHANGER! 4 clips with unique signaling, possibilities are endless. #innovation #bcsm

Exciting times ahead for #BMS in Switzerland! In a recent interview with PharmaBoardroom, Jérome Garcin, the newly appointed General Manager, shared his journey and vision for the strategic role of BMS in Switzerland.    With a focus on making the biggest possible impact for patients, BMS is committed to true innovation—focusing on treatments that are either first-in-market or best-in-market, rather than just adding to the list. This strategy aligns perfectly with Switzerland's emphasis on pioneering health solutions, making it an ideal environment for BMS’s work in oncology, hematology, cardiology, and neurology.   Looking ahead, Jérôme’s priorities include driving growth, advancing BMS’s impressive pipeline, and establishing Switzerland as a global hub for top talent by creating opportunities for learning and professional growth.   Read the whole interview here: https://lnkd.in/gEp4NvV7   #BMSwitzerland #ONEBMS #BMS

As CEO of Sinaptica Therapeutics, Ken is leading the team to advance their personalized closed-loop neuromodulation therapy for Alzheimer's, which has generated unprecedented Phase 2 sham-controlled clinical data that was recently published in Oxford journal, 'Brain.' Sinaptica has FDA Breakthrough status for its novel proprietary approach which combines rTMS, EEG, and Neuronavigation with a sophisticated ML-derived personalization engine based on a novel brain target-- the precuneus, the central hub of the Default Mode Network, a brain network involved in episodic memory. The company has completed all clinicals to date with non-dilutive funding, and is now in-process on a financing to complete the clinical product (SinaptiStim™️ ) and prepare to initiate a pivotal study in 2024. Previously to Sinaptica, Ken has 20+ years leading and growing new business ventures on both the 'Buy Side' and the 'Build Side.' He started his career in management consulting at Charles River Associates, then jumped to industry at CSL, then Baxter BioScience (now Takeda), and Boston Scientific, with leadership roles in marketing, strategy, and corporate development. At Boston Scientific's nearly $1B Neuromodulation division, he was the global commercial lead for the highly successful Cosman RF ablation business he helped acquire. He also built the division’s Strategy function, providing leadership in areas including strategic planning, BD assessment, R&D portfolio management, digital strategy, and investments in next-gen platforms & new indications. Meet Ken Mariash @ #Sachs_NIF More Info @ https://lnkd.in/dHgcp4fq #Neuroscience #Neurotech #NeurologyInnovation #BrainHealth #CNSDisorders #NeurologicalDiseases #ADPD #Neuropsychiatry #PsychedelicResearch #NeuroTechInvestment #Biotech #MedicalInnovation #NeuroscienceForum #NeuroInvestment #NextGenMedicine #NeuroscienceResearch #MentalHealthInnovation #BiotechIndustry

In 2023, neurology slightly surged in R&D partnerships, with 97 compared to 80 in 2022. The total deal value jumped from $10.86 billion in 2022 to $21.10 billion in 2023. Check out our research on our blog. https://hubs.ly/Q02r9SyL0